Respiratory investigation最新文献

{"title":"A summary of the Japanese White Paper on Home Respiratory Care 2024","authors":"Satoshi Hamada ,&nbsp;Jun Ueki ,&nbsp;Toyohiro Hirai ,&nbsp;Emika Sano ,&nbsp;Keiko Hino ,&nbsp;Megumi Ikeda ,&nbsp;Susumu Sato ,&nbsp;Toru Oga ,&nbsp;Tomomasa Tsuboi ,&nbsp;Hajime Kurosawa ,&nbsp;Hiroo Wada ,&nbsp;Japanese White Paper on Home Respiratory Care 2024 working group","doi":"10.1016/j.resinv.2025.04.019","DOIUrl":"10.1016/j.resinv.2025.04.019","url":null,"abstract":"<div><div>The healthcare environment is undergoing rapid transformation, and the importance of resilience in adapting to the VUCA (Volatility, Uncertainty, Complexity, and Ambiguity) era is increasingly recognized across society. Following the White Papers on Home Respiratory Care published in 2005 and 2010, the Japan Respiratory Society, in collaboration with other academic societies and organizations, established the third White Paper on Home Respiratory Care Working Group to evaluate the current status and future directions for home respiratory care. A nationwide survey was conducted from 2021 to 2023, incorporating, for the first time, a dedicated assessment of caregivers and providers, in addition to physician and patient surveys. Among patients receiving long-term oxygen therapy (LTOT), the proportion with chronic obstructive pulmonary disease decreased from 44.8 % in 2010 to 37.0 %, whereas pulmonary fibrosis/interstitial pneumonia increased from 18.2 % to 30.1 %. Inpatient pulmonary rehabilitation was provided by 70.8 %, while outpatient rehabilitation was available at 32.1 %. Overall, 56.3 % of patients sought guidance on recognizing signs of disease exacerbation. And patients had received prior instruction expressed a need for additional education on disaster preparedness. Among caregivers, the average age was 68 years, with 52.7 % reporting health issues classified as modified Medical Research Council grade ≥1. More than half of caregivers perceived caregiving as a significant burden. Additionally, 77.3 % of providers utilized disaster response systems for LTOT patients. These findings underscore the necessity for collaboration among respiratory-related academic societies, government agencies, patients, caregivers, and the media to facilitate comprehensive discussions on sustaining and improving well-being and to enhance information dissemination.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 585-591"},"PeriodicalIF":2.4,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143913111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current treatment landscape for patients with non–small cell lung cancer with common EGFR mutations","authors":"Masayuki Miyata,&nbsp;Hidetoshi Hayashi","doi":"10.1016/j.resinv.2025.04.021","DOIUrl":"10.1016/j.resinv.2025.04.021","url":null,"abstract":"<div><div>Common <em>EGFR</em> mutations including exon-19 deletions and the L858R point mutation in exon 21 constitute predominant actionable genomic alterations in individuals with non–small cell lung cancer (NSCLC). The introduction of EGFR tyrosine kinase inhibitors (TKIs) has fundamentally changed the treatment landscape for such patients by improving both progression-free survival (PFS) and overall survival (OS). Among EGFR-TKIs, third-generation agents such as osimertinib have shown marked efficacy and favorable safety profiles and have become the standard of care in the first-line setting. The combination of osimertinib with platinum-based chemotherapy has recently been shown to improve PFS compared with osimertinib monotherapy in the FLAURA2 trial. Similarly, the MARIPOSA trial demonstrated clinical benefit of the combination of the EGFR-MET bispecific antibody, amivantamab, with the third-generation EGFR-TKI, lazertinib, further supporting the use of combination therapies as first-line treatment for <em>EGFR</em>-mutated NSCLC. Despite these advances, however, challenges such as brain metastases remain substantial barriers to successful treatment outcomes. Management of patients with such metastases often requires a multidisciplinary approach that integrates systemic treatment with local interventions such as radiation therapy. Finally, circulating tumor DNA has emerged as a promising biomarker for real-time monitoring of treatment response and evolution of drug resistance mechanisms. Analysis of such biomarkers can facilitate dynamic and personalized therapeutic adjustments, potentially improving outcomes. This review provides a comprehensive overview of the latest clinical evidence supporting therapeutic advances in the management of <em>EGFR</em>-mutated NSCLC, emphasizing the importance of tailoring treatment strategies based on tumor biology, patient-specific factors, and evolving therapeutic options.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 576-584"},"PeriodicalIF":2.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143908155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of adherence to ICS/LAMA/LABA in patients with asthma: a retrospective observational cohort study using medical claims data","authors":"Toru Oga ,&nbsp;Risako Ito ,&nbsp;Chifuku Mita ,&nbsp;Masashi Takano ,&nbsp;Gema Requena ,&nbsp;Isao Mukai ,&nbsp;Masao Yarita","doi":"10.1016/j.resinv.2025.04.017","DOIUrl":"10.1016/j.resinv.2025.04.017","url":null,"abstract":"<div><h3>Background</h3><div>Real-world evidence of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) use in Japan is limited. This real-world study assessed adherence to FF/UMEC/VI once-daily single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) among patients with asthma in Japan.</div></div><div><h3>Methods</h3><div>Retrospective observational cohort study of patients with asthma initiating FF/UMEC/VI SITT or MITT, using claims data (02/18/2021-02/28/2022, JMDC database). Patients were aged ≥15 years at index (date of FF/UMEC/VI or MITT claim). Outcomes were assessed in two cohorts and weighted using inverse probability of treatment weighting: 1) ‘overall cohort’ included patients who received FF/UMEC/VI or MITT as initial maintenance therapy (IMT) or as non-IMT (i.e., had previously received inhaled corticosteroid-containing medication during baseline); 2) ‘non-IMT cohort’ was a sub-cohort of the overall cohort. Primary outcome: proportion of adherent patients (proportion of days covered ≥0.8) in the 3, 6, and 12 months after, and including, index date.</div></div><div><h3>Results</h3><div>The overall cohort comprised 7228 (FF/UMEC/VI) and 864 (MITT) patients. Of these, 3623 and 735 were included in the FF/UMEC/VI and MITT non-IMT cohort, respectively. At 3 months post-index, a significantly higher proportion of patients were adherent to FF/UMEC/VI (36.4 % [n = 2631]) versus MITT (31.2 % [n = 270]) in the overall cohort (rate ratio [95 % confidence interval], 1.16 [1.05–1.29], p = 0.003, weighted), and FF/UMEC/VI (36.6 % [n = 1326]) versus MITT (28.9 % [n = 213]) in the non-IMT cohort (1.26 [1.12–1.43], p &lt; 0.001). Similar results were observed at 6, and 12 months post-index.</div></div><div><h3>Conclusions</h3><div>Patients with asthma in Japan who initiated FF/UMEC/VI SITT had significantly better treatment adherence than those who initiated MITT.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 569-575"},"PeriodicalIF":2.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143905847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the prevention efficacy of RSV-mediated lower tract disease, immunogenicity and safety in Japanese adults","authors":"Hiroshi Tamura ,&nbsp;Atsushi Momose ,&nbsp;Yumi Takato ,&nbsp;Zheng Richuan ,&nbsp;Arangassery Rosemary Bastian ,&nbsp;Benoit Callendret ,&nbsp;Esther Heijnen","doi":"10.1016/j.resinv.2025.04.016","DOIUrl":"10.1016/j.resinv.2025.04.016","url":null,"abstract":"<div><h3>Background</h3><div>Safety and efficacy of Ad26.RSV.preF/RSV preF-based vaccine in preventing lower respiratory tract disease (LRTD) was assessed in controlled clinical trials globally. This phase 3 study evaluated efficacy, immunogenicity, and safety of Ad26.RSV.preF/RSV preF-based vaccine for respiratory syncytial virus (RSV)-mediated LRTD prevention in Japanese older adults (Cohort 1: ≥60 years), and immunogenicity and safety in Japanese younger adults (Cohort 2: 20–59 years).</div></div><div><h3>Methods</h3><div>The primary objective in Cohort 1 (≥60 years) was to assess the efficacy of vaccine against reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed RSV-mediated LRTD over one RSV season versus placebo; in Cohort 2 the primary objective was to demonstrate non-inferiority of humoral response to RSV vaccine in younger adults versus older adults (20–59 years).</div></div><div><h3>Results</h3><div>In Cohort 1, 2003 participants were randomized (1:1) to vaccine (n = 996) or placebo (n = 1007). None had RSV-mediated LRTD during the first RSV season in vaccine group (study terminated prematurely). In Cohort 2, 180 participants were randomized (3:1) to vaccine (n = 135) or placebo (n = 45). Post-vaccination humoral response in younger adults was found non-inferior to that of older adults. Substantial rise in RSV binding and neutralizing antibody titers from baseline to Day 15 was observed in both Cohorts. Solicited and unsolicited adverse events were more frequent in vaccine group versus placebo group (Cohort 1: 119/149 [79.9 %] and 18/149 [12.1 %] versus 39/150 [26.0 %] and 10/150 [6.7 %]; Cohort 2: 134/138 [97.1 %] and 12/138 [8.7 %] versus 15/46 [32.6 %] and 0/46 [0 %]).</div></div><div><h3>Conclusions</h3><div>Although vaccine efficacy could not be concluded, it was immunogenic with acceptable safety profile in both Japanese younger and older adult population.</div></div><div><h3>Clinical trial registration number</h3><div>NCT05242432</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 560-568"},"PeriodicalIF":2.4,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143898882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis development and survival in idiopathic interstitial pneumonia patients with anti-citrullinated protein antibodies","authors":"Masaru Ito ,&nbsp;Tsukasa Okamoto ,&nbsp;Takashi Shimamura ,&nbsp;Takuya Adachi ,&nbsp;Yuko Okamoto ,&nbsp;Hiroaki Saito ,&nbsp;Toshiharu Tsutsui ,&nbsp;Sao Yoshii ,&nbsp;Shohei Yamashita ,&nbsp;Masayoshi Kobayashi ,&nbsp;Yukihisa Inoue ,&nbsp;Tomoshige Chiaki ,&nbsp;Yoshihiro Miyashita ,&nbsp;Takehiko Oba ,&nbsp;Kazuhito Saito ,&nbsp;Yasunari Miyazaki","doi":"10.1016/j.resinv.2025.04.014","DOIUrl":"10.1016/j.resinv.2025.04.014","url":null,"abstract":"<div><h3>Background</h3><div>Some patients with idiopathic interstitial pneumonia (IIP) with anti-citrullinated protein antibodies (ACPA) develop rheumatoid arthritis (RA) during the early phase of ACPA positivity, whereas others develop RA either in the late phase or not at all; however, the clinical factors that predict RA development and survival outcome in these patients remain unknown.</div></div><div><h3>Methods</h3><div>Retrospective clinical data from IIP patients without an RA diagnosis at the time of ACPA positivity were analysed. The chest high-resolution computed tomography (HRCT) score was calculated based on the extent of the lesions.</div></div><div><h3>Results</h3><div>Of 78 patients enrolled, 46 (59.0 %) were diagnosed with RA during a median observation period of 49.3 months. The cumulative incidence of RA at 48 months was significantly higher in patients with high-positive ACPA than those with low-positive ACPA (67.5 %) <em>vs.</em> 36.3 % low-positive ACPA, <em>p</em> = 0.01). Multivariate analysis identified the high-positive ACPA and the high fibrosis score as significant predictors of RA development (hazard ratio [HR], 3.28, <em>p</em> &lt; 0.01; and HR 1.57, <em>p</em> = 0.02, respectively). Additionally, Cox regression analysis revealed the fibrosis score and glucocorticoids and/or immunosuppressive agent treatment were associated with increased all-cause mortality (HR 1.76, <em>p</em> = 0.02; and HR 3.32, <em>p</em> &lt; 0.01, respectively).</div></div><div><h3>Conclusion</h3><div>In ACPA-positive IIP patients, high-positive ACPA and high fibrosis scores might be the risk factors for imminent RA development. Furthermore, high fibrosis score was associated with poor survival outcomes. Pulmonologists should consider to enlist the help of rheumatologists for patients with high ACPA titres and extensive fibrotic changes.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 554-559"},"PeriodicalIF":2.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positivity of polymerase chain reaction and Grocott staining in relation to the duration from therapy initiation to examination in Pneumocystis jirovecii pneumonia","authors":"Masafumi Shimoda ,&nbsp;Hiroki Nunokawa ,&nbsp;Yoshiaki Tanaka ,&nbsp;Yuuki Bamba ,&nbsp;Toshiaki Kikuchi ,&nbsp;Takashi Ishiguro ,&nbsp;Atsushi Suzuki ,&nbsp;Fumi Kobayashi ,&nbsp;Tatsuya Takahashi ,&nbsp;Ken Ohta ,&nbsp;Haruyuki Ishii","doi":"10.1016/j.resinv.2025.04.013","DOIUrl":"10.1016/j.resinv.2025.04.013","url":null,"abstract":"<div><h3>Introduction</h3><div>The diagnosis of pneumocystis pneumonia (PCP) relies on microscopy and/or polymerase chain reaction (PCR) of bronchoalveolar lavage fluid (BALF). Although <em>Pneumocystis jirovecii</em> can be identified even after therapy initiation, the exact timeframe for reliable testing remains unclear. We investigated the relationship between diagnostic examinations for PCP and the duration from therapy initiation to the time of testing.</div></div><div><h3>Materials and methods</h3><div>We retrospectively collected data from 105 patients diagnosed with PCP based on the diagnostic criteria across four institutions from January 2019 to August 2024. The duration from therapy initiation to the time of testing and the corresponding test results were reviewed.</div></div><div><h3>Results</h3><div>Among 105 patients, 46 and 44 patients underwent <em>P. jirovecii</em> PCR and Grocott staining of BALF, respectively. Fifty-six patients underwent sputum examination. The positivity of <em>P. jirovecii</em> PCR in BALF appeared to decrease after therapy initiation in non–human immunodeficiency virus (HIV) patients. The positivity rate of Grocott staining was low regardless of treatment. All HIV patients had positive <em>P. jirovecii</em> PCR or Grocott staining results in BALF. Among patients with <em>P. jirovecii</em> PCR–positive results in BALF, the duration from therapy initiation to testing was significantly longer in HIV patients than in non–HIV patients (2.5 days [range 0–7] vs. 0 days [0–4], <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>For non-HIV patients who have already received anti–PCP therapy, the use of BALF for PCP diagnosis should be performed as early as possible. In contrast, HIV-positive patients can still be diagnosed with PCP after therapy initiation.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 548-553"},"PeriodicalIF":2.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a risk score to predict community-acquired pneumonia occurrence in the adult population","authors":"Mateu Serra Prat ,&nbsp;Angel Lavado Cuevas ,&nbsp;Ignasi Bolibar Ribas ,&nbsp;Elisabet Palomera Fanegas ,&nbsp;Jordi Almirall Pujol ,&nbsp;the GEMPAC Group","doi":"10.1016/j.resinv.2025.04.012","DOIUrl":"10.1016/j.resinv.2025.04.012","url":null,"abstract":"<div><h3>Background</h3><div>Community-acquired pneumonia (CAP) preventive strategies can benefit from a quantification of individual CAP risk. This study develops and validates a CAP Risk Score (CAP-RS) for the adult population to predict CAP occurrence in the next five years.</div></div><div><h3>Methods</h3><div>The development phase was as follows: a population-based case-control study to identify potential CAP risk factors for inclusion in the CAP-RS after weighting according to odds ratios; development of a numerical scoring system for weighted risk factors; and establishment of cut-off points to discriminate between different risk levels. The validation phase consisted of a population-based case-control study and a retrospective cohort study (with 47 836 adults aged ≥18 years corresponding to three Maresme (Barcelona) primary care centres) followed up over a five-year period (2015–2019).</div></div><div><h3>Results</h3><div>786 new CAP cases were identified. 15 factors were included in the CAP-RS. Risk was higher in subjects with CAP than without CAP (4.5 vs 1.9; p &lt; 0.001), and the association (OR) between the CAP-RS and the occurrence of CAP increased as the CAP-RS value increased. AUC-ROC was 0.67 (p &lt; 0.001). Cut-offs were established at &lt;1, &lt;5, and &lt;10 points as best discriminating between risk groups. Annual CAP incidence was 1.9, 3.1, 6.2, and 12.4 new cases/10³ inhabitants for the no, moderately, severely, and very severely increased risk groups, respectively. Significant differences in CAP-free survival were observed between the four CAR-RS categories.</div></div><div><h3>Conclusions</h3><div>The 15-item CAP-RS, which stratifies risk with good validity, can aid in the design and implementation of preventive CAP strategies for adult populations.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 542-547"},"PeriodicalIF":2.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest Advances in Perioperative care for Resectable Non-small lung cancer","authors":"Yuko Oya ,&nbsp;Ichidai Tanaka","doi":"10.1016/j.resinv.2025.04.001","DOIUrl":"10.1016/j.resinv.2025.04.001","url":null,"abstract":"<div><div>Resectable non-small cell lung cancer (NSCLC) has a relatively poor prognosis owing to the risk of developing local or distant metastatic recurrence, even at stage I. To overcome the high recurrence rate, perioperative therapies have been rapidly developed through the combination of existing cytotoxic chemotherapies with immune checkpoint inhibitors (ICIs) and molecular targeted therapies. These new therapeutic strategies have significantly improved the prognosis of patients with stage II–III NSCLC and have been approved for clinical use. However, new challenges have emerged in the selection of the optimal perioperative treatment in clinical practice. First, it is currently difficult to determine which perioperative treatment is superior, preoperative or postoperative. Additionally, since surgery alone is curative in some patients, the addition of anticancer agents such as ICIs raises concerns regarding toxicity, as serious side effects during preoperative treatment may lead to an inability to perform the surgery itself. Moreover, because various perioperative treatments are still being developed, treatment options for perioperative care are expected to increase soon. To summarize the increasingly complex perioperative treatment of resectable NSCLC, this review provides a comprehensive summary of the clinical efficacies of current perioperative therapies and future directions based on basic background, patient selection, ongoing trials, and enhancing immunotherapy.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 532-541"},"PeriodicalIF":2.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of drug-induced interstitial pneumonia in Japan","authors":"Miwa Yamanaka ,&nbsp;Atsuhito Ushiki ,&nbsp;Koichiro Tatsumi ,&nbsp;Akihiko Gemma ,&nbsp;Noboru Hattori ,&nbsp;Yoichi Tanaka ,&nbsp;Yoshiro Saito ,&nbsp;Masayuki Hanaoka","doi":"10.1016/j.resinv.2025.04.015","DOIUrl":"10.1016/j.resinv.2025.04.015","url":null,"abstract":"<div><h3>Background</h3><div>Japan has a higher incidence of drug-induced interstitial pneumonia (IP) than other countries. Understanding the clinical characteristics of drug-induced IP in Japan will facilitate accurate diagnosis of the disease. The aim of this study was to analyze and report the clinical characteristics of drug-induced IP in Japan.</div></div><div><h3>Methods</h3><div>We analyzed the characteristics of drug-induced IP diagnosed between 2009 and 2022 in Japan. Case data were collated with the cooperation of pharmaceutical companies, as requested by the Ministry of Health, Labour and Welfare.</div></div><div><h3>Results</h3><div>We identified 285 patients with drug-induced IP diagnosed in medical institutions. The most common causative drugs identified were antineoplastic agents (56.1 %). Common subjective symptoms included dyspnea (158 patients [55.4 %]), cough (132 patients [46.3 %]), and fever (115 patients [40.4 %]). In addition, 177 patients (73.1 % of those measured) showed elevated serum KL-6, SP-D, or SP-A levels. Approximately 60 % of the patients developed IP within 90 days from the initiation of drug therapy, whereas 15 % developed the disease after &gt;1 year. Regarding imaging findings, 249 patients (87.4 %) showed bilateral shadows. Corticosteroid therapy was administered to 222 patients (77.9 %). The treatment outcomes of drug-induced IP in Japan were favorable, with improvement observed in 273 patients (95.8 %).</div></div><div><h3>Conclusions</h3><div>Dyspnea, cough, and fever after administration of a drug; elevated serum KL-6, SP-D, and SP-A levels; and bilateral shadows were identified as clinical features of drug-induced IP in Japan. Drug-induced IP should be considered a differential diagnosis even if the patient started using the causative drug long ago.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 524-531"},"PeriodicalIF":2.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases of bronchial artery aneurysms in patients with long-standing precapillary pulmonary hypertension","authors":"Taku Komori ,&nbsp;Takahiro Sato ,&nbsp;Ichizo Tsujino ,&nbsp;Daisuke Tamatsuki ,&nbsp;Shuhei Yoshikawa ,&nbsp;Hideki Shima ,&nbsp;Junichi Nakamura ,&nbsp;Ryo Morita ,&nbsp;Daisuke Abo ,&nbsp;Satoshi Konno","doi":"10.1016/j.resinv.2025.04.011","DOIUrl":"10.1016/j.resinv.2025.04.011","url":null,"abstract":"<div><div>Bronchial artery aneurysm (BAA) is a rare but increasingly recognized condition due to advances in imaging. We report two cases of BAA in patients with long-standing pulmonary hypertension. Case 1 is a 30-year-old man with idiopathic peripheral pulmonary artery stenosis diagnosed at age 23. He developed a slightly dilated bronchial artery, which later enlarged, leading to bronchial artery embolization. Case 2 is a 30-year-old woman with pulmonary arterial hypertension diagnosed at age 3. Multiple BAAs were identified at age 24, and progressive enlargement was observed at age 28. Due to lesion complexity, she remains under careful observation.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 521-523"},"PeriodicalIF":2.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}